Easy USMLE Oncology Practice Questions

Concept Explanation

Oncology in the context of the USMLE Step 1 and Step 2 exams focuses on the molecular basis of cancer, clinical presentations of common malignancies, and the mechanisms of action for chemotherapeutic agents. Understanding oncology requires a firm grasp of cell cycle regulation, proto-oncogenes, and tumor suppressor genes. For instance, the TP53 gene is the most frequently mutated gene in human cancer, acting as a guardian of the genome by inducing cell cycle arrest or apoptosis in response to DNA damage. You should be familiar with the hallmarks of cancer, which include self-sufficiency in growth signals, insensitivity to anti-growth signals, and the ability to evade apoptosis. These foundational concepts are essential for solving Easy USMLE Oncology Practice Questions because they allow you to deduce the behavior of specific tumors based on their genetic or cellular characteristics. While studying, using a personalized study plan can help you organize these complex pathways into manageable daily tasks. Additionally, recognizing paraneoplastic syndromes—symptoms that occur at sites distant from a tumor or its metastasis—is a high-yield skill for the exam.

Solved Examples

1. Genetic Predisposition: A 25-year-old female presents with multiple colon polyps. Genetic testing reveals a mutation in the APC gene on chromosome 5.
   1. Identify the condition: Familial Adenomatous Polyposis (FAP).
   2. Determine the inheritance pattern: Autosomal dominant.
   3. Assess the risk: Without prophylactic colectomy, the risk of colorectal cancer is nearly 100% by age 40.
2. Tumor Markers: A 65-year-old male with a history of chronic hepatitis C presents with weight loss and right upper quadrant pain. Laboratory studies show an elevated alpha-fetoprotein (AFP).
   1. Identify the likely malignancy: Hepatocellular carcinoma (HCC).
   2. Recall other associations: AFP is also elevated in yolk sac tumors.
   3. Confirm the diagnosis: Imaging typically shows a hypervascular mass on CT or MRI.
3. Pharmacology: A patient undergoing chemotherapy for breast cancer develops hemorrhagic cystitis.
   1. Identify the causative agent: Cyclophosphamide or ifosfamide.
   2. Explain the mechanism: These alkylating agents produce acrolein, a toxic metabolite that irritates the bladder lining.
   3. Determine the preventive measure: Administering Mesna (2-mercaptoethane sulfonate) and aggressive hydration.

Practice Questions

1. A 32-year-old woman presents with a firm, painless lump in her left breast. Biopsy reveals a malignant tumor that overexpresses the HER2/neu receptor. Which of the following is a monoclonal antibody specifically targeting this receptor?

2. A 60-year-old male smoker presents with a persistent cough and hemoptysis. A chest X-ray shows a central hilar mass. Laboratory results reveal a serum calcium level of $12.5 \text{ mg/dL}$. Which lung cancer subtype is most likely responsible for this paraneoplastic production of parathyroid hormone-related protein (PTHrP)?

3. A 4-year-old boy is brought to the pediatrician due to a large, palpable abdominal mass that does not cross the midline. The child has hematuria but is otherwise asymptomatic. What is the most likely diagnosis?

4. A patient with Small Cell Lung Cancer (SCLC) presents with hyponatremia and concentrated urine. This is likely due to the ectopic secretion of which hormone?

5. A 55-year-old woman is treated with Doxorubicin for lymphoma. What is the most significant long-term side effect associated with this medication that requires monitoring via echocardiogram?

6. In chronic myeloid leukemia (CML), a reciprocal translocation between chromosomes 9 and 22 creates the BCR-ABL fusion gene. What type of protein does this gene encode?

7. A 70-year-old man presents with bone pain and "punched-out" lytic lesions on a skull X-ray. Serum protein electrophoresis (SPEP) shows an M-spike. Which cell type is proliferating malignantly in this condition?

8. Which chemotherapeutic agent acts by inhibiting dihydrofolate reductase (DHFR), thereby decreasing the synthesis of thymidine and purines?

Answers & Explanations

1. Trastuzumab: This monoclonal antibody binds to the extracellular domain of the HER2/neu (ERBB2) receptor, which is a tyrosine kinase. It is used in HER2-positive breast and gastric cancers.
2. Squamous Cell Carcinoma: Squamous cell carcinoma of the lung is often centrally located and is classically associated with hypercalcemia due to the production of PTHrP. Remember the "4 S's": Squamous, Smoker, Sentral (Central), and Stones (Hypercalcemia).
3. Wilms Tumor (Nephroblastoma): This is the most common renal malignancy in children. Unlike neuroblastoma, a Wilms tumor typically presents as a smooth, unilateral mass that does not cross the midline.
4. Antidiuretic Hormone (ADH): Small cell lung cancer is known for causing the Syndrome of Inappropriate ADH (SIADH), leading to water retention, dilutional hyponatremia, and high urine osmolality.
5. Dilated Cardiomyopathy: Anthracyclines like Doxorubicin generate free radicals that cause cardiotoxicity. This can lead to congestive heart failure, making baseline and follow-up ejection fraction measurements vital.
6. Tyrosine Kinase: The BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives uncontrolled cell proliferation. It is the target of the drug Imatinib.
7. Plasma Cells: Multiple Myeloma is a malignancy of plasma cells. These cells produce large amounts of monoclonal immunoglobulins (M-protein) and can lead to hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB). For more on blood-related cancers, see our USMLE Hematology Pathology Practice Questions.
8. Methotrexate: Methotrexate is a folate analog that competitively inhibits DHFR. This prevents the conversion of dihydrofolate to tetrahydrofolate, halting DNA synthesis.

1. Which of the following tumor markers is specifically used to monitor the recurrence of colorectal cancer?

• ACA-125
• BCarcinoembryonic antigen (CEA)
• CAlpha-fetoprotein (AFP)
• DPSA

Frequently Asked Questions

What is the difference between a proto-oncogene and a tumor suppressor gene?

A proto-oncogene is a normal gene that promotes cell growth, but when mutated into an oncogene, it causes gain-of-function and uncontrolled growth. In contrast, a tumor suppressor gene normally inhibits cell division, and its loss-of-function leads to cancer development.

Why is the TNM staging system used in oncology?

The TNM system stands for Tumor size, Node involvement, and Metastasis, providing a standardized way to describe the extent of cancer. It is critical for determining prognosis and selecting the most appropriate treatment strategy for the patient.

What are the most common sites of cancer metastasis?

Cancer cells most frequently spread to the regional lymph nodes, liver, lungs, and bones. The specific pattern of spread often depends on the primary tumor's venous drainage and proximity to these organs.

How does Imatinib work in treating CML?

Imatinib is a small molecule inhibitor that specifically targets the ATP-binding site of the BCR-ABL tyrosine kinase. By blocking this site, it prevents the protein from signaling the cell to divide, effectively stopping the progression of Chronic Myeloid Leukemia.

What is the significance of the BRCA1 and BRCA2 genes?

BRCA1 and BRCA2 are tumor suppressor genes involved in DNA repair via homologous recombination. Mutations in these genes significantly increase the lifetime risk of developing breast and ovarian cancers in women, as well as prostate cancer in men.